The DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells
Open accessAbstract
GPRC5D is an attractive target for immunotherapy of myeloma, and optimized GPRC5D-targeted CAR T cells eradicate myeloma xenografts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“GPRC5D (G protein-coupled receptor, class C, group 5, member D) is a G-protein-coupled orphan receptor that highly expressed in malignant bone marrow plasma cells from CD138+ MM patients. Its expression in normal tissues is primarily limited to the hair follicle region. Importantly, GPRC5D is expressed independently of BCMA, making it a promising target for multiple myeloma therapy [214, 215].”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [214]
The cited source says what the claim attributes to it.
In the citing paper
“One such promising target is GPRC5D, which has shown independent expression from BCMA and has demonstrated excellent anti-tumor activity in MM models with BCMA loss.”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [214]
In the citing paper
“GPRC5D expression is enriched in malignant plasma cells and is associated with markers of high-risk myeloma. 13,14,16,19-21”
From Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma (2022) · cites this paper as [16]
In the citing paper
“GPRC5D expression is enriched in malignant plasma cells and is associated with markers of high-risk myeloma. 13,14,16,19-21”
From Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma (2022) · cites this paper as [16]
In the citing paper
“Given the localized expression of GPRC5D in nail beds in mice, 15-17”
From Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma (2022) · cites this paper as [16]
In the citing paper
“Given the localized expression of GPRC5D in nail beds in mice, 15-17 nail toxic effects are probably related to on-target talquetamab activity.”
From Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma (2022) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688
Self-citationEfficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
Self-citationBlinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Kantarjian, H. M., Stein, A. S., Gökbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J., Wei, A. H., Dombret, H., Foà, R., Bassan, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609783 · Cited by 2,204
Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815
Fry, T. J., Shah, N. N., Orentas, R. J., Stetler‐Stevenson, M., Yuan, C. M., Ramakrishna, S., Wolters, P. L., Martin, S. C., Delbrook, C., Yates, B., et al. (2017) · Nature Medicine · doi:10.1038/nm.4441 · Cited by 1,363
Sotillo, E., Barrett, D. M., Black, K. L., Bagashev, A., Oldridge, D. A., Wu, G. S., Sussman, R. T., Lanauze, C. B., Ruella, M., Gazzara, M. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1020 · Cited by 1,279
Turtle, C. J., Hanafi, L.-A., Berger, C., Hudecek, M., Pender, B., Robinson, E., Hawkins, R., Chaney, C., Cherian, S., Chen, X., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf8621 · Cited by 1,016 · cited 14×
“R. Gardner, D. Wu, S. Cherian, M. Fang, L.-A. Hanafi, O. Finney, H. Smithers, M. C. Jensen, S. R. Riddell, D. G. Maloney, C. J. Turtle, Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy.”
InfluentialBrudno, J. N., Marić, I., Hartman, S. D., Rose, J. J., Wang, M., Lam, N., Stetler‐Stevenson, M., Salem, D., Yuan, C. M., Pavletic, S. Z., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.8084 · Cited by 792
Research works printed but not linked: 1
- A. D. Cohen, A. L. Garfall, E. A. Stadtmauer, S. F. Lacey, E. Lancaster, D. T. Vogl, B. M. Weiss, D. E. Ambrose, A. M. Nelson, F. Chen, G. Plesa, I. Kulikovskaya, V. Gonzalez, M. Gupta, R. M. Young, K. Dengel, L. O’keefe, S. Le, C. Richardson, R. E. Isaacs, J. J. Melenhorst, B. L. Levine, C. H. June, M. C. Milone, Safety and efficacy of B-cell maturation antigen (BCMA)-specific chimeric antigen receptor T cells (CART-BCMA) with cyclophosphamide conditioning for refractory multiple myeloma (MM). Blood 130, 505 (2017).
Cited by
Sorted by citations
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0297-y · Cited by 1,525
Self-citationClinical implications of T cell exhaustion for cancer immunotherapy
Chow, A., Perica, K., Klebanoff, C. A., & Wolchok, J. D. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00689-z · Cited by 1,044
Recent advances and discoveries in the mechanisms and functions of CAR T cells
Larson, R. C., & Maus, M. V. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00323-z · Cited by 852
Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
Chari, A., Minnema, M. C., Berdeja, J. G., Oriol, A., van de Donk, N. W. C. J., Rodríguez-Otero, P., Askari, E., Mateos, M.-V., Costa, L. J., Caers, J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204591 · Cited by 744
CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
Zhang, X., Zhu, L., Zhang, H., Chen, S., & Xiao, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.927153 · Cited by 460
GPRC5D-Targeted CAR T Cells for Myeloma
Mailankody, S., Devlin, S. M., Landa, J., Nath, K., Diamonte, C., Carstens, E. J., Russo, D., Auclair, R., Fitzgerald, L., Cadzin, B., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2209900 · Cited by 411
Self-citationCAR-T design: Elements and their synergistic function
Jayaraman, J., Mellody, M., Hou, A. J., Desai, R. P., Fung, A., Pham, A. H. T., Chen, Y. Y., & Zhao, W. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102931 · Cited by 403
Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma
Lee, H., Ahn, S., Maity, R., Leblay, N., Ziccheddu, B., Truger, M. S., Chojnacka, M., Cirrincione, A. M., Durante, M. A., Tilmont, R., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02491-5 · Cited by 370
Kaplon, H., Chenoweth, A. M., Crescioli, S., & Reichert, J. M. (2022) · mAbs · doi:10.1080/19420862.2021.2014296 · Cited by 347
Hansen, D. K., Sidana, S., Peres, L. C., Colin, C., Shune, L. O., Shrewsbury, A. M., Gonzalez, R. M., Sborov, D. W., Wagner, C. B., Dima, D., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01365 · Cited by 305
CAR T cell therapies for patients with multiple myeloma
Mikkilineni, L., & Kochenderfer, J. N. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0427-6 · Cited by 277
Wittsten, A. H., Yang, S., Park, M., Garcia, J. M., Alavi, J., Perry, N., Montgomery, G., Liu, B., & Roybal, K. T. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd8836 · Cited by 262
Fernández de Larrea, C., Staehr, M., Lopez, A. V., Ng, K. Y., Chen, Y., Godfrey, W. D., Purdon, T. J., Ponomarev, V., Wendel, H.-G., Brentjens, R. J., et al. (2020) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0020 · Cited by 223
Self-citationA bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
Mei, H., Li, C., Jiang, H., Zhao, X., Huang, Z., Jin, D., Guo, T., Kou, H., Liu, L., Tang, L., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01170-7 · Cited by 222
Dagar, G., Gupta, A., Masoodi, T., Nisar, S., Merhi, M., Hashem, S., Chauhan, R., Dagar, M., Mirza, S., Bagga, P., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04292-3 · Cited by 229
Immunotherapy of multiple myeloma
Minnie, S. A., & Hill, G. R. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129205 · Cited by 220
Verkleij, C. P. M., Broekmans, M. E. C., van Duin, M., Frerichs, K. A., Kuiper, R., de Jonge, A. V., Kaiser, M., Morgan, G., Axel, A., Boominathan, R., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003805 · Cited by 182
Pillarisetti, K., Edavettal, S., Mendonça, M., Li, Y., Tornetta, M., Babich, A., Majewski, N., Husovsky, M., Reeves, D., Walsh, E., et al. (2020) · Blood · doi:10.1182/blood.2019003342 · Cited by 174
CAR T-cell therapy in hematologic malignancies: a voyage in progress.
Holstein, S. A., & Lunning, M. A. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1674 · Cited by 172
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects
Tang, L., Huang, Z., Mei, H., & Hu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01521-5 · Cited by 181
Zhang, M., Wei, G., Zhou, L., Zhou, J., Chen, S., Zhang, W., Wang, D., Luo, X., Cui, J., Huang, S., et al. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00372-6 · Cited by 166
Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma
Barwick, B. G., Gupta, V. A., Vertino, P. M., & Boise, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01121 · Cited by 184
Emerging immunotherapies in multiple myeloma
Shah, U. A., & Mailankody, S. (2020) · BMJ · doi:10.1136/bmj.m3176 · Cited by 160
Rodríguez‐Otero, P., Usmani, S. Z., Cohen, A. D., van de Donk, N. W. C. J., Leleu, X. P., Pérez‐Larraya, J. G., Manier, S., Nooka, A. K., Mateos, M., Einsele, H., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00043-3 · Cited by 157
Signaling from T cell receptors (TCRs) and chimeric antigen receptors (CARs) on T cells
Wu, L., Wei, Q., Brzostek, J., & Gascoigne, N. R. J. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0470-3 · Cited by 164
Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?
D’Agostino, M., & Raje, N. S. (2019) · Leukemia · doi:10.1038/s41375-019-0669-4 · Cited by 155
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies
Tapia‐Galisteo, A., Álvarez‐Vallina, L., & Sanz, L. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01482-w · Cited by 147
Comparative analysis of assays to measure CAR T cell-mediated cytotoxicity
Kiesgen, S., Messinger, J. C., Chintala, N. K., Tano, Z., & Adusumilli, P. S. (2021) · Nature Protocols · doi:10.1038/s41596-020-00467-0 · Cited by 138
Ferguson, I., Patiño-Escobar, B., Tuomivaara, S. T., Lin, Y.-H. T., Nix, M. A., Leung, K., Kasap, C., Ramos, E., Vasquez, W. N., Talbot, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31810-6 · Cited by 124
Chari, A., Touzeau, C., Schinke, C., Minnema, M. C., Berdeja, J. G., Oriol, A., van de Donk, N. W. C. J., Rodríguez-Otero, P., Morillo, D., Martinez-Chamorro, C., et al. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00385-5 · Cited by 116
GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review
Rodriguez-Otero, P., van de Donk, N. W. C. J., Pillarisetti, K., Cornax, I., Vishwamitra, D., Gray, K., Hilder, B., Tolbert, J., Renaud, T., Masterson, T., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-023-00966-9 · Cited by 113
Oekelen, O. V., Nath, K., Mouhieddine, T. H., Farzana, T., Aleman, A., Melnekoff, D. T., Ghodke‐Puranik, Y., Shah, G. L., Lesokhin, A. M., Giralt, S. A., et al. (2022) · Blood · doi:10.1182/blood.2022017848 · Cited by 109
Parikh, R. H., & Lonial, S. (2023) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21771 · Cited by 107
Bispecific Antibodies in Multiple Myeloma: Present and Future
Lancman, G., Sastow, D. L., Cho, H. J., Jagannath, S., Madduri, D., Parekh, S. S., Richard, S., Richter, J. R., Sanchez, L. J., & Chari, A. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0028 · Cited by 102
Development of CAR-T cell therapies for multiple myeloma
Gagelmann, N., Riecken, K., Wolschke, C., Berger, C., Ayuk, F. A., Fehse, B., & Kröger, N. (2020) · Leukemia · doi:10.1038/s41375-020-0930-x · Cited by 102
Xia, J., Li, H., Yan, Z., Zhou, D., Wang, Y., Qi, Y., Cao, J., Li, D., Cheng, H., Sang, W., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01824 · Cited by 94
Self-citationBispecific antibodies in the treatment of multiple myeloma
Devasia, A. J., Chari, A., & Lancman, G. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01139-y · Cited by 94
Truger, M. S., Duell, J., Zhou, X., Heimeshoff, L., Ruckdeschel, A. M., John, M., Riedel, A., Hueper, S., Peter, J., Walter, W., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004418 · Cited by 92
Mohan, M., Chakraborty, R., Bal, S., Nellore, A., Baljević, M., D’Souza, A., Pappas, P. G., Berdeja, J. G., Callander, N. S., & Costa, L. J. (2023) · British Journal of Haematology · doi:10.1111/bjh.18909 · Cited by 91
Multiple myeloma: signaling pathways and targeted therapy
Lu, Q., Yang, D., Li, H., Niu, T., & Tong, A. (2024) · Molecular biomedicine · doi:10.1186/s43556-024-00188-w · Cited by 90
Holstein, S. A., Grant, S. J., & Wildes, T. M. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00512 · Cited by 93
Determinants of Response and Mechanisms of Resistance of CAR T-cell Therapy in Multiple Myeloma
van de Donk, N. W. C. J., Themeli, M., & Usmani, S. Z. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0227 · Cited by 90
Verkleij, C. P. M., O’Neill, C. A., Broekmans, M. E. C., Frerichs, K. A., Bruins, W. S. C., Duetz, C., Kruyswijk, S., Baglio, S. R., Skerget, S., Oca, R. M. D., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3333 · Cited by 93
Timmers, M., Roex, G., Wang, Y., Campillo-Davó, D., Tendeloo, V. F. V., Chu, Y., Berneman, Z. N., Luo, F., Acker, H. H. V., & Anguille, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01613 · Cited by 86
CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions
Rodríguez‐Lobato, L. G., Ganzetti, M., de Larrea, C. F., Hudecek, M., Einsele, H., & Danhof, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01243 · Cited by 88
Herrera, N. G., Morano, N. C., Celikgil, A., Georgiev, G. I., Malonis, R. J., Lee, J. H., Tong, K., Vergnolle, O., Massimi, A. B., Yen, L. Y., et al. (2020) · ACS Omega · doi:10.1021/acsomega.0c03512 · Cited by 84
Self-citationMultiple Myeloma Therapy: Emerging Trends and Challenges
Dima, D., Jiang, D., Singh, D. J., Hasipek, M., Shah, H., Ullah, F., Khouri, J., Maciejewski, J. P., & Jha, B. K. (2022) · Cancers · doi:10.3390/cancers14174082 · Cited by 92
Rejeski, K., Jain, M. D., & Smith, E. L. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.04.007 · Cited by 81
Self-citationRevolutionizing cancer treatment: a comprehensive review of CAR-T cell therapy
Dabas, P., & Danda, A. (2023) · Medical Oncology · doi:10.1007/s12032-023-02146-y · Cited by 86
Lee, H., Neri, P. E., & Bahlis, N. J. (2024) · Blood · doi:10.1182/blood.2023022499 · Cited by 79
Phage display derived peptides for Alzheimer's disease therapy and diagnosis
Zhang, X., Zhang, X., Gao, H., & Qing, G. (2022) · Theranostics · doi:10.7150/thno.68636 · Cited by 75
Allogeneic TCRαβ deficient CAR T-cells targeting CD123 in acute myeloid leukemia
Sugita, M., Galetto, R., Zong, H., Ewing-Crystal, N. A., Trujillo-Alonso, V., Mencia-Trinchant, N., Yip, W., Filipe, S., Lebuhotel, C., Gouble, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29668-9 · Cited by 78
Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside
Zhang, B., Yang, M., Zhang, W., Liu, N., Wang, D., Jing, L., Xu, N., Yang, N., & Ren, T. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06438-7 · Cited by 73
Li, Y., Ming, Y., Fu, R., Li, C., Wu, Y., Jiang, T., Li, Z., Ni, R., Li, L., Su, H., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.950923 · Cited by 75
CAR‐T cell therapy in hematological malignancies: Where are we now and where are we heading for?
Khan, A. N., Asija, S., Pendhari, J., & Purwar, R. (2023) · European Journal Of Haematology · doi:10.1111/ejh.14076 · Cited by 72
Zhou, D., Sun, Q., Xia, J., Gu, W., Qian, J., Zhuang, W., Yan, Z., Cheng, H., Chen, W., Zhu, F., et al. (2024) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00176-5 · Cited by 69
Tumor buster - where will the CAR-T cell therapy ‘missile’ go?
Qu, C., Zhang, H., Cao, H., Tang, L., Mo, H., Liu, F., Zhang, L., Yi, Z., Long, L., Yan, L., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01669-8 · Cited by 68
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
Kegyes, D., Constantinescu, C. S., Vrancken, L., Rasche, L., Grégoire, C., Țigu, A. B., Gulei, D., Dima, D. M., Tănase, A., Einsele, H., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01296-2 · Cited by 65
CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges
Rendo, M. J., Joseph, J. J., Phan, L. M., & DeStefano, C. B. (2022) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s327016 · Cited by 68
Roex, G., Feys, T., Beguin, Y. P., Kerre, T. C. C., Poiré, X., Lewalle, P., Vandenberghe, P., Bron, D., & Anguille, S. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020194 · Cited by 65
Sottile, R., Panjwani, M. K., Lau, C. M., Daniyan, A. F., Tanaka, K., Barker, J. N., Brentjens, R. J., Sun, J. C.-Y., Luduec, J.-B. L., & Hsu, K. C. (2021) · Science Immunology · doi:10.1126/sciimmunol.abe6968 · Cited by 67
Self-citationBispecific antibodies in multiple myeloma treatment: A journey in progress
Cho, S., Yeh, T., Anderson, K. C., & Tai, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1032775 · Cited by 63
Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma
Davis, L. N., & Sherbenou, D. W. (2021) · Cancers · doi:10.3390/cancers13071686 · Cited by 63
Hammons, L. R., Szabó, A., Janardan, A., Bhatlapenumarthi, V., Annyapu, E., Dhakal, B., Hadidi, S. A., Radhakrishnan, S. V., Narra, R. K., Bhutani, D., et al. (2023) · Haematologica · doi:10.3324/haematol.2023.283590 · Cited by 61
Bispecific T‐cell engagers for treatment of multiple myeloma
Ravi, G., & Costa, L. J. (2022) · American Journal of Hematology · doi:10.1002/ajh.26628 · Cited by 61
Targeted Therapy With Immunoconjugates for Multiple Myeloma
Bruins, W. S. C., Zweegman, S., Mutis, T., & van de Donk, N. W. C. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01155 · Cited by 60
Overcoming the Immunosuppressive Tumor Microenvironment in Multiple Myeloma
Uckun, F. M. (2021) · Cancers · doi:10.3390/cancers13092018 · Cited by 57
In vitro profiling of orphan G protein coupled receptor (GPCR) constitutive activity
Watkins, L. R., & Orlandi, C. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15468 · Cited by 59
Holthof, L. C., van der Schans, J. J., Katsarou, A., Poels, R., Gelderloos, A. T., Drent, E., Veen, S. E. V. H.-V., Li, F., Zweegman, S., van de Donk, N. W. C. J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2188 · Cited by 55
BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma
Cho, S., Lin, L., Xing, L., Li, Y., Yu, T., Anderson, K. C., & Tai, Y. (2020) · Cancers · doi:10.3390/cancers12061473 · Cited by 57
Clinical management of patients with relapsed/refractory multiple myeloma treated with talquetamab
Chari, A., Krishnan, A., Rasche, L., Ye, J. C., Garfall, A., Popat, R., Lipe, B., Qin, X., Campagna, M., Masterson, T., et al. (2024) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2024.05.003 · Cited by 53
A review of antibody-based therapeutics targeting G protein-coupled receptors: an update
Hutchings, C. J. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1745770 · Cited by 53
Bispecific antibodies: unleashing a new era in oncology treatment
Shui, L., Wu, D., Yang, K., Sun, C., Li, Q., & Yin, R. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02390-y · Cited by 51
BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma
Yang, J., Zhou, W., Li, D., Niu, T., & Wang, W. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215949 · Cited by 51
Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma
Larson, R. C., Kann, M. C., Graham, C., Mount, C., Castaño, A. P., Lee, W., Bouffard, A. A., Takei, H. N., Almazan, A. J., Scarfò, I., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43416-7 · Cited by 49
Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma
García‐Guerrero, E., Sierro-Martínez, B., & Pérez‐Simón, J. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01128 · Cited by 48
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma
Bruno, B., Wäsch, R., Engelhardt, M. M., Gay, F., Giaccone, L., D’Agostino, M., Rodríguez‐Lobato, L. G., Danhof, S., Gagelmann, N., Kröger, N. M., et al. (2021) · Haematologica · doi:10.3324/haematol.2020.276402 · Cited by 48
Immunotherapy for the treatment of multiple myeloma
Boussi, L. S., Avigan, Z. M., & Rosenblatt, J. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1027385 · Cited by 48
CAR T and CAR NK cells in multiple myeloma: Expanding the targets
Shah, U. A., & Mailankody, S. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101141 · Cited by 47
Keshavarz, A., Salehi, A., Khosravi, S., Shariati, Y., Nasrabadi, N., Kahrizi, M. S., Maghsoodi, S., Mardi, A., Azizi, R., Jamali, S., et al. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03163-w · Cited by 47
New Biological Therapies for Multiple Myeloma
Garfall, A. L. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-050522-033815 · Cited by 47
Dual Targeting with CAR T Cells to Limit Antigen Escape in Multiple Myeloma
Simon, S., & Riddell, S. R. (2020) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0122 · Cited by 45
Anderson, L. D., Dhakal, B., Jain, T., Oluwole, O. O., Shah, G. L., Sidana, S., Perales, M., & Pasquini, M. C. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.10.022 · Cited by 48
T-cell–redirecting bispecific antibodies in multiple myeloma: a revolution?
Moreau, P., & Touzeau, C. (2022) · Blood · doi:10.1182/blood.2021014611 · Cited by 46
Shah, N. D., Aiello, J., Avigan, D., Berdeja, J. G., Borrello, I., Chari, A., Cohen, A. D., Ganapathi, K. A., Gray, L., Green, D. J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000734 · Cited by 47
Self-citationChallenges and strategies associated with CAR-T cell therapy in blood malignancies
Liu, Z., Lei, W., Wang, H., Liu, X., & Fu, R. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00490-x · Cited by 43
Dhakal, B., Akhtar, O. S., Fandrei, D., Jensen, A. M., Banerjee, R. K., Pan, D., Richard, S., Friend, R. N., Rees, M. J., Costello, P., et al. (2025) · Blood · doi:10.1182/blood.2025029773 · Cited by 43
Guo, Z., Tu, S., Yu, S., Wu, L., Pan, W., Chang, N., Zhou, X., Song, C., Li, Y., & He, Y. (2021) · Cancer Science · doi:10.1111/cas.14799 · Cited by 45
Lakshman, A., & Kumar, S. K. (2021) · American Journal of Hematology · doi:10.1002/ajh.26379 · Cited by 44
Bispecific Antibodies in Multiple Myeloma: Opportunities to Enhance Efficacy and Improve Safety
Swan, D., Murphy, P. T., Glavey, S. V., & Quinn, J. (2023) · Cancers · doi:10.3390/cancers15061819 · Cited by 42
Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies
Yang, C., Nguyen, J., & Yen, Y. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00982-8 · Cited by 44
CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond
Mishra, A. K., Gupta, A., Dagar, G., Das, D., Chakraborty, A., Haque, S., Prasad, C. P., Singh, A. K., Bhat, A. A., Macha, M. A., et al. (2023) · Vaccines · doi:10.3390/vaccines11111721 · Cited by 40
Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma
Cho, S., Xing, L., Anderson, K. C., & Tai, Y. (2021) · Cancers · doi:10.3390/cancers13236136 · Cited by 41
Hernández‐Rivas, J., Ríos, R., Encinas, C., Alonso, R., & Lahuerta, J. J. (2022) · Biomarker Research · doi:10.1186/s40364-021-00344-2 · Cited by 40
Controlling Cell Trafficking: Addressing Failures in CAR T and NK Cell Therapy of Solid Tumours
White, L. G., Goy, H. E., Rose, A. J., & McLellan, A. D. (2022) · Cancers · doi:10.3390/cancers14040978 · Cited by 41
CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma
Martino, M. V., Canale, F. A., Alati, C., Vincelli, I. D., Moscato, T., Porto, G., Loteta, B., Naso, V., Mazza, M., Nicolini, F., et al. (2021) · Cancers · doi:10.3390/cancers13112639 · Cited by 40
Ng, B. D., Rajagopalan, A., Kousa, A. I., Fischman, J. S., Chen, S., Massa, A., Elias, H. K., Manuele, D., Galiano, M., Lemarquis, A. L., et al. (2024) · Blood · doi:10.1182/blood.2023022293 · Cited by 40
Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches
Noh, J., Seo, H., Lee, J., & Jung, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218000 · Cited by 40
CAR-T-Cell-Based Cancer Immunotherapies: Potentials, Limitations, and Future Prospects
Choudhery, M. S., Arif, T., Mahmood, R., & Harris, D. T. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13113202 · Cited by 40
Metadata
- Authors
- Smith, E. L., Harrington, K., Staehr, M., Masakayan, R., Jones, J., Long, T. J., Ng, K. Y., Ghoddusi, M., Purdon, T. J., Wang, X., Do, T., Pham, M. T., Brown, J. M., De Larrea, C. F., Olson, E., Peguero, E., Wang, P., Liu, H., Xu, Y., Garrett-Thomson, S. C., Almo, S. C., Wendel, H.-G., Riviere, I., Liu, C., Sather, B., & Brentjens, R. J.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Juno Therapeutics (United States) (US)
- Cellular Therapeutics Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
- Sloan Kettering Institute, New York, NY 10065, USA.
- Eureka Therapeutics (United States) (US)
- Albert Einstein College of Medicine (US)
- Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
- Eureka Therapeutics, Emeryville, CA 94608, USA.
- Corresponding author
- Brentjens, Renier J.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2019-03-27
- Volume
- 11
- Issue
- 485
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC7508042
- OpenAlex
- W2923396001
- Cited by
- 391
- References
- 35
- Citations by year
- 2026: 31 · 2025: 55 · 2024: 79 · 2023: 68 · 2022: 46 · 2021: 55 · 2020: 42 · 2019: 14
- FWCI
- 16.36
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (R01 CA198095, R01 HG008325)
- National Cancer Institute (P30 CA008748, U54 OD020355-01, PO1 CA190174-01, P01 CA059350, P30 CA013330, R01 CA138738-05)
- Multiple Myeloma Research Foundation
- American Society of Hematology
- Leukemia and Lymphoma Society
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- GPRC5D, multiple myeloma, CAR T-cell therapy, BCMA, scFv, phage display
- MeSH terms
- Receptors, Chimeric Antigen, Animals, Antibody Specificity, Humans, Multiple Myeloma, RNA, Messenger, Gene Expression, Immunotherapy, Adoptive, Mice, SCID, Mice, Inbred NOD, Xenograft Model Antitumor Assays, Receptors, G-Protein-Coupled, Cell Line, Tumor, Mice, B-Cell Maturation Antigen, Single-Chain Antibodies, Translational Research, Biomedical
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
